ScreenerHero

PTGXProtagonist Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · protagonist-inc.com
154.32USD+2.41%Mkt Cap: 9.99B $P/E: 146.97

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric p…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap9.99B $
Enterprise Value8.98B $
Revenue (TTM)281.99M $
Gross Profit281.99M $
Net Income (TTM)-130.15M $
Revenue/Share4.358 USD
Last Price154.32 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees141
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)146.97
P/E (Forward)2542.00
PEG—
EV/EBITDA149.92
EV/Revenue31.84
P/S34.58
P/B11.58
EPS (TTM)1.01
EPS (Forward)0.06
52W Range
54.5094% of range160.81
52W High160.81 USD
52W Low54.50 USD
Profitability
Gross Margin100.00%
Oper. Margin74.37%
EBITDA Margin21.24%
Profit Margin-282.83%
ROE-21.17%
ROA-19.48%
Growth
Revenue Growth3749.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF57.67M $
CapEx (TTM)1.59M $
FCF Margin34.10%
FCF Yield0.96%
Net Debt-773.36M $
Net Debt/EBITDA-12.91
Balance Sheet
Debt/Equity0.02
Current Ratio21.71
Quick Ratio21.58
Book Value/Sh13.01 USD
Cash/Share12.09 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)170.38 USD
Upside (mean)+10.4%
Target Range149.00 USD – 225.00 USD
$149.00+10.4% to mean$225.00
# Analysts13
Ownership
Shares Out.64.71M
Float52.89M
Insiders0.71%
Institutions119.81%
Short Interest
Short Ratio11.0d
Short % Float13.55%
Short % Out.11.66%
Shares Short7.54M
Short (prev mo.)7.69M
Technical
SMA 50133.23 (+15.8%)
SMA 200102.34 (+50.8%)
Beta1.79
S&P 52W Chg18.16%
Avg Vol (30d)526.38K
Avg Vol (10d)474.48K
Technical Indicators
RSI (14)63.5
MACD6.6875
MACD Signal6.3935
MACD Hist.+0.2940
BB Upper161.79 USD
BB Middle144.48 USD
BB Lower127.17 USD
BB Width23.96%
ATR (14)5.611 USD
Vol Ratio (20d)0.84x